No active 13F manager changed its position in Protagenic Therapeutics, Inc.\new last quarter. Over the last 180 days, 1 insider bought and none sold, a net +$31K in open-market trades.
The legs disagree, or only one of them leans.
Not held in any tracked 13F filing yet.
Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| Aug 21, 2026 | Armen Garo H | EXEC. CHAIR & PRINCIPAL OFF, Director | Buy (P) | 20K | $13K |
| Aug 20, 2026 | Armen Garo H | EXEC. CHAIR & PRINCIPAL OFF, Director | Buy (P) | 17K | $10K |
| Aug 19, 2026 | Armen Garo H | EXEC. CHAIR & PRINCIPAL OFF, Director | Buy (P) | 3K | $945 |
| Aug 11, 2026 | Armen Garo H | EXEC. CHAIR & PRINCIPAL OFF, Director | Buy (P) | 2K | $710 |
| Aug 6, 2026 | Armen Garo H | EXEC. CHAIR & PRINCIPAL OFF, Director | Buy (P) | 685 | $151 |
| Aug 5, 2026 | Armen Garo H | EXEC. CHAIR & PRINCIPAL OFF, Director | Buy (P) | 5K | $1K |
| Jul 30, 2026 | Armen Garo H | EXEC. CHAIR & PRINCIPAL OFF., Director | Buy (P) | 26K | $5K |
| Oct 12, 2023 | Arrow Alexander K. | Chief Financial Officer | Buy (P) | 8K | $6K |
| May 18, 2022 | Arrow Alexander K. | Chief Financial Officer | Buy (P) | 8K | $6K |
| May 17, 2022 | Arrow Alexander K. | Chief Financial Officer | Buy (P) | 23K | $16K |
| Apr 30, 2021 | Arrow Alexander K. | Chief Financial Officer | Buy (P) | 1K | $2K |
| Apr 29, 2021 | Arrow Alexander K. | Chief Financial Officer | Buy (P) | 1K | $2K |
Where institutional funds (13F), corporate insiders (Form 4) and US House members (STOCK Act) are buying or selling the same name in the same window. Green is buying, red is selling.
Insiders and Congress: last 180 days. Funds: latest 13F, top 100 holders incl. passive
| Source | Buying | Selling | Net |
|---|---|---|---|
13F funds Top 100 holders by value, passive included; the hero counts active managers only | 0 | 0 | – |
Insiders Form 4 open-market | 1 | 0 | +$31K |
US House STOCK Act trades | 0 | 0 | $0 |
Capital Rotation reports where institutional capital disclosed rotating, as of the latest public SEC 13F filings. It is data, not investment advice, a recommendation, or a prediction. Filings lag about 45 days and cover long US equity positions only. Past disclosed flows do not indicate future prices. Do your own research; consult a licensed advisor.
Connected entities for Protagenic Therapeutics, Inc.\new
This stock page is the public Follow view. For one current, evidence-backed answer, use capital_change_brief through REST or MCP. It compares tracked 13F changes with qualifying Form 4 activity and cites the SEC evidence.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/stocks/ATRN/capital-change-brief"
Use Arkolith's capital_change_brief for Protagenic Therapeutics, Inc.\new. Tell me what changed, whether insider activity corroborates it, and cite the SEC evidence.
13F holdings + Form 4 insider transactions + the live filing stream, joined for ATRN. Filings are public domain, sourced to SEC EDGAR.